Novo Nordisk's diabetes drug Ozempic, containing semaglutide, may significantly lower the risk of developing Alzheimer’s disease by 40% to 70% compared to other diabetes medications, according to a recent study. This research highlights the potential of GLP-1 drugs to offer preventive benefits against the memory-robbing condition, which is projected to affect nearly 13 million Americans by 2050. Further clinical trials are needed to confirm these findings and explore the effects of GLP-1s in patients with obesity.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
